[HTML][HTML] Physiologically based pharmacokinetic (PBPK) modeling to predict PET image quality of three generations EGFR TKI in advanced-stage NSCLC patients
IH Bartelink, EA van de Stadt, AF Leeuwerik… - Pharmaceuticals, 2022 - mdpi.com
Introduction: Epidermal growth factor receptor (EGFR) mutated NSCLC is best treated using
an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR …
an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR …
[HTML][HTML] Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients
IH Bartelink, EA van de Stadt, AF Leeuwerik… - …, 2022 - ncbi.nlm.nih.gov
Introduction: Epidermal growth factor receptor (EGFR) mutated NSCLC is best treated using
an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR …
an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR …
[PDF][PDF] Physiologically-based pharmacokinetic (PBPK) modeling to predict PET image quality of three generations EGFR TKI in advanced-stage NSCLC patients
IH Bartelink, EA van de Stadt, AF Leeuwerik, V Thijssen… - NSCLC - research.vu.nl
Introduction: Epidermal growth factor receptor (EGFR) mutated NSCLC is best treated using
an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR …
an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR …
Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients.
IH Bartelink, EA van de Stadt… - Pharmaceuticals …, 2022 - search.ebscohost.com
Introduction: Epidermal growth factor receptor (EGFR) mutated NSCLC is best treated using
an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR …
an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR …
Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients
IH Bartelink, EA van de Stadt… - Pharmaceuticals …, 2022 - pubmed.ncbi.nlm.nih.gov
Introduction Epidermal growth factor receptor (EGFR) mutated NSCLC is best treated using
an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR …
an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR …
Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients
IH Bartelink, EA van de Stadt, AF Leeuwerik… - …, 2022 - search.proquest.com
Introduction: Epidermal growth factor receptor (EGFR) mutated NSCLC is best treated using
an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR …
an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR …
Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients.
IH Bartelink, EA van de Stadt, AF Leeuwerik… - Pharmaceuticals …, 2022 - europepmc.org
Methods Relevant physicochemical and drug specific properties (eg, pKa, lipophilicity, target
binding) for each TKI were collected and applied in established base PBPK models. Key …
binding) for each TKI were collected and applied in established base PBPK models. Key …
Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients
IH Bartelink, EA van de Stadt… - …, 2022 - researchinformation.amsterdamumc …
Introduction: Epidermal growth factor receptor (EGFR) mutated NSCLC is best treated using
an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR …
an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR …